List of Excipients in Branded Drug METFORMIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	CANDELILLA WAX
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	CELLULOSE ACETATE
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	FERROSOFERRIC OXIDE
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	HYPROMELLOSES
Actavis Pharma Inc	METFORMIN HYDROCHLORIDE	metformin hydrochloride	0591-2719	MAGNESIUM STEARATE

Generic Drugs Containing METFORMIN

Company	Ingredient	NDC	Excipient
A-S Medication Solutions	metformin er 500 mg	50090-6515	HYPROMELLOSE
A-S Medication Solutions	metformin er 500 mg	50090-6515	MAGNESIUM STEARATE
A-S Medication Solutions	metformin er 500 mg	50090-6515	POVIDONE
A-S Medication Solutions	metformin er 500 mg	50090-6516	HYPROMELLOSE 2208
A-S Medication Solutions	metformin er 500 mg	50090-6516	HYPROMELLOSE 2910

What are the Most Frequently-Used Excipients in METFORMIN?

# Of NDCs	Excipient
3	ETHYLCELLULOSES
3	HYDROXYPROPYL CELLULOSE
2	HYPROMELLOSE
11	HYPROMELLOSE 2208
11	HYPROMELLOSE 2910

Excipient Strategy and Commercial Opportunities for Metformin

Last updated: February 26, 2026

What are the key excipient considerations for Metformin?

Metformin hydrochloride, the active pharmaceutical ingredient (API), is typically formulated as immediate-release tablets. Its formulation relies heavily on excipients that influence stability, bioavailability, manufacturability, and patient compliance. Common excipients include:

• Binders: Hydroxypropyl methylcellulose (HPMC), microcrystalline cellulose (MCC)
• Fillers: Lactose monohydrate, microcrystalline cellulose
• Disintegrants: Croscarmellose sodium, sodium starch glycolate
• Lubricants: Magnesium stearate
• Glidants: Colloidal silicon dioxide
• Colorants and coatings: Depending on branded formulations, colorants like titanium dioxide or film coatings for taste masking

Optimal excipient selection balances formulation stability with manufacturing process constraints, ensuring consistent drug release and patient acceptance.

How does excipient choice impact commercial opportunities?

1. Product Differentiation: Incorporating novel or improved excipients allows for extended-release formulations, reducing dosing frequency. Extended-release metformin commands higher price points and can enhance patient adherence, boosting market share.

2. Manufacturing Efficiency: Excipient blends that optimize flowability and compressibility reduce production costs. Use of excipients compatible with high-speed manufacturing supports large-scale production and rapid market deployment.

3. Patent Opportunities: Proprietary excipient formulations enable innovation exclusivity, potentially extending patent life or creating new IP in generic markets.

4. Formulations for Special Populations: Excipients compatible with pediatric or geriatric tablet formulations expand clinical reach and market size.

What are current market trends and innovations in excipient strategies for Metformin?

• Alternative Excipients: Cheaper or more stable fillers, such as plant-based cellulose derivatives, are being explored to reduce costs without compromising quality.
• Polypill Approaches: Combining metformin with other agents (e.g., SGLT2 inhibitors) in a single formulation requires excipient compatibility analysis, opening avenues for combination products.
• Taste Masking and Patient Compliance: Use of more effective taste-masking excipients, such as certain polymers, improves palatability, especially for pediatric formulations.

How do regulatory policies influence excipient strategies?

Regulatory agencies, such as the FDA or EMA, require:

• GRAS (Generally Recognized As Safe) status for excipients in oral solid dosages.
• Documentation of excipient safety, especially for new or novel excipients.
• Clear specifications for excipient quality, which affect formulation development timelines.

Regulatory approval paths are streamlined for formulations using well-established excipients, but novel excipients may require additional safety and efficacy data, impacting time-to-market.

What are the commercial opportunities in excipient supply?

• High-demand excipients: MCC, lactose, croscarmellose sodium are widely used, with global markets valued at billions. The growth of generic and branded metformin tablets sustains demand.
• Innovation-driven niches: Excipient companies that develop bioavailability-enhancing polymers or taste-masking agents can target premium formulations.
• Geographic expansion: Markets in Asia, Africa, and Latin America increasingly adopt metformin, offering opportunities for localized excipient supply chains and tailored formulations.

Summary of key data points

Aspect	Details
Typical excipients in metformin	MCC, lactose, croscarmellose, magnesium stearate
Market size of excipients	Global excipient market exceeds USD 10 billion (2022 estimate)
Extended-release market	Expected CAGR of 5.2% (2022-2027) driven by formulations
Regulatory considerations	Use of GRAS excipients; safety profiles required
Innovation opportunities	Bioavailability enhancement, taste masking, combination pills

Key Takeaways

• Excipient selection for metformin influences formulation stability, cost, and patient compliance.
• Novel excipients enable extended-release or combination products, increasing market share.
• Regulatory frameworks favor established excipients but allow innovation with safety data.
• The global demand for metformin supports stable supply chains of core excipients.
• Innovation in taste masking and bioavailability presents niche opportunities for excipient suppliers.

FAQs

Q1: What excipients are most common in metformin immediate-release formulations?
Microcrystalline cellulose, lactose monohydrate, croscarmellose sodium, and magnesium stearate.

Q2: How does excipient choice affect the bioavailability of metformin?
It influences drug disintegration and dissolution rate, impacting absorption. Excipients like certain polymers can enhance bioavailability.

Q3: Are there opportunities to develop proprietary excipient blends for metformin?
Yes. Custom blends targeting extended-release profiles or improved manufacturing can provide differentiation and patent positions.

Q4: What regulatory challenges exist when introducing new excipients?
New excipients require comprehensive safety data and approval processes, potentially delaying product launch.

Q5: How might excipient innovation impact the global metformin market?
It can lead to improved formulations, cost efficiencies, and access in emerging markets, expanding overall market potential.

---

References

1. Ahuja, A., Thakur, M., & Singh, S. (2020). Pharmaceutical excipients: New developments and future prospects. Journal of Pharmaceutical Innovation, 15(2), 186–202.

2. MarketsandMarkets. (2022). Excipients Market by Type, Function, Application, and Region. Retrieved from https://www.marketsandmarkets.com

3. U.S. Food and Drug Administration. (2020). Guidance for Industry: Excipients in Finished Drug Products for Human Use.

4. European Medicines Agency. (2021). Guideline on the use of excipients in medicinal products for human use.

5. Rajpoot, P., & Narang, P. (2019). Extended-release formulations: A practical approach. International Journal of Pharmaceutical Investigation, 9(4), 137–148.